Jiyon Chu

Jiyon Chu

Auto-generated profile, based on publicly available information

Jiyon Chu

Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in Infection & Chemotherapy
Verified
Journal Article
Open access
NKNa Yung Kim
Na Yung Kim
DKDo Young Kim
Do Young Kim
JCJiyon Chu
Jiyon Chu
SJSeungHyun Jung
SeungHyun Jung
Kim NY, et al. Infect Chemother. 2023 Jun;55:e22. https://doi.org/10.3947/ic.2023.0037

30 September 2021 in Genomics & Informatics
Verified
Journal Article
Open access
PDF file
JCJiyon Chu
Jiyon Chu
JSJuyoun Shin
Juyoun Shin
SKShinseok Kang
Shinseok Kang
SSSun Shin
Sun Shin
Yeun-Jun ChungYeun-Jun Chung
Yeun-Jun Chung
Salmonella species are among the major pathogens that cause foodborne illness outbreaks. In this study, we aimed to develop a loop-mediated isothermal amplification (LAMP) assay for the rapid and sensitive detection of Salmonella species. We designed LAMP primers targeting the hilA gene as a universal marker of Salmonella species. A total of seven Salmonella species strains and 11 non-Salmonella pathogen strains from eight different genera were used in this study. All Salmonella strains showed positive amplification signals with the Salmonella LAMP assay; however, there was no non-specific amplification signal for the non-Salmonella strains. The detection limit was 100 femtograms (20 copies per reaction), which was ~1,000 times more sensitive than the detection limits of the conventional polymerase chain reaction (PCR) assay (100 pg). The reaction time for a positive amplification signal was less than 20 minutes, which was less than one-third the time taken while using conventional PCR. In conclusion, our Salmonella LAMP assay accurately detected Salmonella species with a higher degree of sensitivity and greater rapidity than the conventional PCR assay, and it may be suitable for point-of-care testing in the field.

4 April 2025 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
JCJiyon Chu
Jiyon Chu
IYIn Hyuk Yoo
In Hyuk Yoo
IYIn Young Yoo
In Young Yoo
JSJeong-ih Shin
Jeong-ih Shin
YPYeon-Joon Park
Yeon-Joon Park
Hyun Mi Kang, M.D., Ph.D., Jiyon Chu, M.S., In Hyuk Yoo, M.D., Ph.D., In Young Yoo, M.D., Ph.D., Jeong-Ih Shin, Ph.D., Mi-Ran Seo, Ph.D., Yeun-Jun Chung, M.D., Ph.D., Seung-Hyun Jung, Ph.D., and Yeon Joon Park, M.D., Ph.D.. Ann Lab Med 2025;45:312-21. https://doi.org/10.3343/alm.2024.0378

2 May 2022 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
JLJinok Lee
Jinok Lee
JCJiyon Chu
Jiyon Chu
GJGyuyeon Jang
Gyuyeon Jang
MLMinho Lee
Minho Lee
Yeun-Jun ChungYeun-Jun Chung
Yeun-Jun Chung
Background: Recent deep sequencing technologies have proven to be valuable resources to gain insights into the expression profiles of diverse tRNAs. However, despite these technologies, the association of tRNAs with diverse diseases has not been explored in depth because analytical tools are lacking. Results: We developed a user-friendly tool, tRNA Expression Analysis Software Utilizing R for Easy use (tReasure), to analyze differentially expressed tRNAs (DEtRNAs) from deep sequencing data of small RNAs using R packages. tReasure can quantify individual mature tRNAs, isodecoders, and isoacceptors. By adopting stringent mapping strategies, tReasure supports the precise measurement of mature tRNA read counts. The whole analysis workflow for determining DEtRNAs (uploading FASTQ files, removing adapter sequences and poor-quality reads, mapping and quantifying tRNAs, filtering out low count tRNAs, determining DEtRNAs, and visualizing statistical analysis) can be performed with the tReasure package. Conclusions: tReasure is an open-source software available for download at https://treasure.pmrc.re.kr and will be indispensable for users who have little experience with command-line software to explore the biological implication of tRNA expression.

17 July 2025 in Microbial Genomics
Verified
Journal Article
Open access
JSJeong-ih Shin
Jeong-ih Shin
SCSung-Yeon Cho
Sung-Yeon Cho
JCJiyon Chu
Jiyon Chu
CPChulmin Park
Chulmin Park
MLMinho Lee
Minho Lee
DLDong-Gun Lee
Dong-Gun Lee
Streptococcus pneumoniae, a clinically significant pathogen, causes invasive diseases in children and older adults. Pneumococcal conjugate vaccines (PCVs) have substantially reduced the incidence of vaccine serotype (VT) pneumococcal diseases. However, serotype replacement, characterized by the emergence of non-vaccine serotypes (NVTs), presents a persistent challenge to disease prevention. To address this, we analysed 236 pneumococcal isolates collected in South Korea between 1997 and 2023, spanning both pre- and post-PCV13 periods. Whole-genome sequencing was performed to assess serotypes, antimicrobial resistance, virulence factors and global pneumococcal sequence clusters (GPSCs). Capsular switching events and the relationships among pneumococcal lineages, serotypes and disease invasiveness were also evaluated. Among the 37 identified serotypes, NVTs such as 23A, 15B/15C and 10A were dominant post-PCV13. Serotype 10A, associated with invasive pneumococcal diseases (IPDs), belonged to GPSC634-ST11189 and showed elevated minimum inhibitory concentrations for β-lactams. Capsular switching events were observed between VTs and NVTs, highlighting the adaptability of pneumococcal populations. Antimicrobial non-susceptibility was highest for azithromycin (82.7%), followed by tetracycline (76.5%) and co-trimoxazole (70.4%), with higher rates observed in the post-PCV13 period. Notably, amoxicillin (P=0.049) and meropenem (P=0.002) showed significant non-susceptibility in the post-PCV13 period. Virulence factors pspA and pfbA were associated with IPDs, while pilus islet PI-1-related genes were more frequent in non-invasive cases. These findings underscore the importance of genomic surveillance to monitor pneumococcal population dynamics and inform public health strategies. The inclusion of serotype 10A in the recently approved PCV20 offers promise for further reducing the global burden of IPDs, including in South Korea.